News
InvestorsHub on MSN58m
ProMIS Neurosciences stock price surges in pre market trading as company receives FDA fast track designation for alzheimer’s drug candidate PMN310ProMIS Neurosciences Inc. (Nasdaq:PMN), a clinical-stage biotechnology firm specializing in treatments for neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback